We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sharehunter, I can sell all my holdings, but I can't buy without NT
NT to buy ,are mms filling a large order
Sharehunter; Agree, very good feel and momentum now...and I am off for a cuppa now. :-)
thought might reach £4 ,some might take profit now at this level , in my view shows the strength of buyers interest in the potential at ncyt
hamsters18, He's multi-posting to keep his thread at the top of the board.
Once £4 clears, £5 should take to long to blast through. Just sit tight and enjoy the ride. GLA
Chrishar; so am I, but trying to double your post count in one day is a bit OTT, lol.
He's excited Hamster and there's not much else to discuss right now.
Good reaction to the rns. I thought it was run-of-the-mill but the gross margin and EBITDA figures are striking.
Sooo many shorts closing!
Bungle66; yes getting within striking distance now, now in the crosshairs.
like how many buyers now ,picking up shares again
Sharehunter, I enjoy your enthusiasm and positive posts, but have a tea break.
with the number of buyers now that replacing the sellers ,hoping a strong finish ,good to see these seller out and being replaced by buyers before more news is released
like how new buyers replacing sellers ,thinking will £4 be seen this morning or afternoon ,as sellers being replaced with different buyers
bought some more ,,before next move up
• Primerdesign revenue increased over 2,000% to €70.6m (H1 2019: €3.3m) due to the success of the COVID-19 product portfolio
Financial highlights
• Group consolidated unaudited revenue increased over 900% to €72.4m (H1 2019: €7.2m)
• Primerdesign revenue increased over 2,000% to €70.6m (H1 2019: €3.3m) due to the success of the COVID-19 product portfolio
• Group gross margin strengthened to 83%, delivering a gross profit of €60.3m, an increase of 20% from H1 2019 (63%)
• Primerdesign maintained its strong gross margin, delivering 85% in H1 2020 (H1 2019: 86%), demonstrating strong control of margins as the business is scaled
• Group EBITDA of €49.4m (H1 2019: €0.2m)
• Operating profit of €48.3m compared to a loss of €0.7m in H1 2019, driven by the growth in sales in molecular products business
• Profit after tax of €40.2m compared to a loss of €1.2m in H1 2019
• Cash at 30 June 2020 of €19.7m after paying down all long-term debt and significant working capital investment made into stock to ensure the continuity of supply to meet the demand for COVID-19 tests
Summary highlights
• H1 2020 sales of €72.4 million and EBITDA of €49.4 million, resulting from the sale of the Company's market leading PCR COVID-19 test, has transformed Novacyt
• Performance provides period end cash of €19.7m, following repayment of all debt and significant investment in inventory
• New strategy implemented to continue growth trajectory and consolidate performance through broadening focus on respiratory and transplant clinical diagnostics
• Visibility of orders for the Company's COVID-19 product portfolio suggests H2 2020 performance on track to exceed that of H1 2020
will £4 be seen this time, buys building nicely
• Acquisition of specific assets to enable Novacyt to expand its core capabilities whilst maintaining attractive margins
watch out for more news ,be my view ,
Strategy update highlights
• New strategy to focus on organic, R&D and acquisitive growth in the respiratory and transplant bacterial and viral diagnostic markets
• Investment in R&D and commercial infrastructure to deliver new products and establish a direct sales force in key markets in the US and across Europe
• Selective product/technology and company acquisitions to generate additional revenues and profits to offset potential future reductions in COVID-19 revenues and enhance the Group's trajectory towards becoming a market leader in respiratory and transplant clinical diagnostics
• Acquisition of specific assets to enable Novacyt to expand its core capabilities whilst maintaining attractive margins
• Investment in developing new IP portfolio to enhance and secure future value
85% margin
buys moving in again ,another move up looks to be coming again
We must remember that we started the week at £3.35 and we're still yet to get the news we're all waiting for. Might take a few more weeks to really rocket...
It is going to get smashed!